Anyone follow Celanese Corporation (CE)? Looking attractively undervalued....
Not following, but from Morningstar:
Maintaining $160 FVE as Celanese Reports Fourth-Quarter Results; Shares Undervalued
Analyst Note | Updated Feb 24, 2023
After updating our model to incorporate Celanese's fourth-quarter results, we maintain our $160 per share fair value estimate. Our narrow moat rating is also unchanged.
Although management guided to a lower outlook in 2023 than the initial view presented during the company's third quarter earnings call, the midpoint of adjusted EPS guidance was slightly above the consensus mean based on PitchBook data. As such, the market reacted positively to the outlook, with shares up 2% at the time of writing on a day when the broader market is down 1.5%.
However, at current prices, we view Celanese shares as undervalued, with the stock trading more than 25% below our fair value estimate and in 4-star territory. As a result, we view current prices as a good entry point for long-term investors to pick up shares of the high-quality specialty chemicals producer.
In our view, an economic slowdown in 2023 will represent a cyclical bottom for Celanese's earnings, after reaching a peak in 2021. Thereafter, we expect Celanese will be well positioned to generate strong results driven by volume growth for its downstream engineered materials as the company integrates the recently acquired DuPont mobility and materials business. As global auto builds recover and electric vehicle adoption grows, Celanese is well-positioned to see long-term profit growth.
We have also updated our Morningstar Uncertainty Rating for Celanese to High from Medium. The change is to reflect a wide range of outcomes due to Celanese's elevated debt levels and the continued volatility of energy prices. This can greatly affect the company's more-commoditized acetyl chain business.
Business Strategy and Outlook | Updated Feb 24, 2023
Celanese is the world's largest producer of acetic acid and its chemical derivatives, including vinyl acetate monomer and emulsions. These products are used in the company’s specialized end products or sold externally. Celanese produces these commodity chemicals in its acetyl chain segment (roughly 65% of 2022 pro forma EBITDA including acquisitions), which primarily serves the automotive, cigarette, coatings, building and construction, and medical end markets. Celanese's Clear Lake, Texas, plant benefits from a cost advantaged feedstock from low-cost U.S. natural gas. The company plans to expand acetic acid production capacity at Clear Lake by roughly 50%, which should benefit segment margins thanks to lower unit production costs relative to other geographies.
The engineered materials, or EM, segment (35%) produces specialty polymers for a wide variety of end markets. Celanese is investing in the expansion of this business through acquisition. The company acquired Santoprene in late 2021 and acquired the majority of DuPont's mobility and materials portfolio in late 2022. Both deals add complementary products to Celanese's existing portfolio. Going forward, the EM segment should generate roughly 50% of profits in 2023 and grow to account for the majority of profits thereafter.
The automotive industry will account for the majority of EM segment revenue, while other key end markets include electronics. EM uses commodity chemicals, such as acetic acid, methanol, and ethylene to produce specialty polymers. Celanese should benefit from automakers lightweighting vehicles, or replacing small metal pieces with lighter plastic pieces. Celanese should also see growth from increasing electric vehicle and hybrid adoption, as the company will sell multiple components specific to these powertrains. By 2030, we forecast two thirds of all new global auto sales will be EVs or hybrids.
Fair Value and Profit Drivers | Updated Feb 24, 2023
Our fair value estimate is $160 per share. Our valuation assumes an 8.2% weighted average cost of capital. The marginal cost sources for many of Celanese’s commodity chemicals are oil-based naphtha or higher-cost European or Asian natural gas. However, Celanese produces the majority of its chemicals from low-cost U.S. natural gas feedstock. As such, the company benefits from a wider spread between U.S. natural gas and either Brent oil or European and Asian natural gases.
As the company integrates the DuPont and Santoprene acquisitions, we expect EBITDA margins in the engineered materials segment to grow from the low to mid-20% range on a pro forma basis to the high-20% range in a midcycle environment. We think Celanese will capture the majority of cost-saving synergies from the DuPont deal, leading to margin expansion over time.
We forecast the acetyl chain segment to see lower profits versus the cyclical peak in 2021 due to strong demand and tight supply conditions. While profits fell in 2022, we expect conditions will continue to moderate, leading to another step down in 2023. By the middle of the decade, we forecast the business will grow slowly in a midcycle environment due to exposure to mostly mature end markets. We expect EBITDA margins for the acetyl chain business, which primarily sells acetic acid, to fall back to the mid-20s from the 38% level achieved in 2021 (including the acetate tow business which is now a part of acetyl chain).
In a scenario where Celanese sees prolonged volume decline due to an economic slowdown and an EU natural gas shortage, we would forecast revenue growth to average low-single-digits, while operating margins would fall from lower capacity utilization. This scenario also assumes a tepid recovery from the slowdown. Our fair value estimate would fall to $90 per share.